ArticleDeutsches Arzteblatt international2019
The Prevalence, Comorbidity, Management and Costs of Irritable Bowel Syndrome.
Article in Deutsches Arzteblatt international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Cost-of-Illness of Irritable Bowel Syndrome: A Systematic Review.Journal of gastroenterology and hepatology · 2026Pooled it
- Pelvic Congestion Syndrome: The Gynecological Perspective.Journal of clinical medicine · 2026Review
- Gastrointestinal Motility Function and Dysfunction in the Elderly Patient: What Are the Effects of Aging?Visceral medicine · 2024Review
- Building a Neurogastroenterology Unit: Why, Where, and How?Visceral medicine · 2024Review
- Link between irritable bowel syndrome, depression, and colorectal cancer risk in young patients: Age-matched nationwide population-based study.World journal of gastrointestinal pathophysiology · 2024Article
- Body constitutions of traditional Chinese medicine caused a significant effect on irritable bowel syndrome.Journal of the Chinese Medical Association : JCMA · 2024Article
- Differential effects of hypnotherapy and cognitive behavioral therapy on the default mode network of depressed patients.Frontiers in psychology · 2024Article
- Health care utilizations and costs of Campylobacter enteritis in Germany: A claims data analysis.PloS one · 2023Article
- Overlap between irritable bowel syndrome and common gastrointestinal diagnoses: a retrospective cohort study of 29,553 outpatients in Germany.BMC gastroenterology · 2022Article
- Bright, but allergic and neurotic? A critical investigation of the "overexcitable genius" hypothesis.Frontiers in psychology · 2022Article
- Linaclotide utilization and potential for off-label use and misuse in three European countries.Therapeutic advances in gastroenterology · 2022Article
- Illness perception and health care use in individuals with irritable bowel syndrome: results from an online survey.BMC family practice · 2021Article
- [Diverticula in the gastrointestinal tract].Der Internist · 2021Article
- The fecal mycobiome in patients with Irritable Bowel Syndrome.Scientific reports · 2021Article
- Co-occurrence of pain syndromes.Journal of neural transmission (Vienna, Austria : 1996) · 2020Review
- In Reply.Deutsches Arzteblatt international · 2019Article
- Anaerobic Cause.Deutsches Arzteblatt international · 2019Article
- "Psychogenic" is Not the Be-All and End-All.Deutsches Arzteblatt international · 2019Article
Corrections and comments
- Commented on byAnaerobic Cause.2019
- Commented on by
- Commented on byIn Reply.2019
Authors and funding
4 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInsufficient data are available on the administrative incidence and prevalence of irritable bowel syndrome (IBS) in Germany, as well as on its comorbidities, diagnostic evaluation, treatment, and costs.
methodsWe analyzed routine data from a statutory health insurance carrier with approximately eight million insurees. IBS was identified from the ICD-10 codes K58.0, K58.9, and F45.32 (outpatient care by a physician, outpatient and inpatient care in a hospital). The cumulative incidence for the year 2017 was determined by the exclusion of insurees who had carried the diagnosis of IBS in any of the preceding 12 years. The frequencies of comorbid diseases and of diagnostic and therapeutic measures were compared with those of persons in age- and sex- matched control groups without IBS.
resultsIn 2017, the administrative incidence of IBS was 0.36%, and its prevalence was 1.34%. Persons with IBS were often documented as having other gastrointes- tinal diseases, headache, back pain, and mental disorders. There was evidence for the insufficient use of ultrasound and colonoscopy and for the excessive use of computed tomography and magnetic resonance imaging for diagnostic evaluation. The costs of medical care for insurees with IBS in the year of their initial diagnosis were higher than those of other insurees without the diagnosis of IBD (€ 3770 vs. € 2788) and rose in each of the eight years preceding the initial diagnosis.
conclusionPatients with IBS in Germany are likely not receiving sufficient diag- nostic evaluation in conformity with the relevant guidelines. The high prevalence of comorbid mental disorders and other pain syndromes implies that the complaints of patients with IBS need to be more comprehensively evaluated and treated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.